国家: 美国
语言: 英文
来源: NLM (National Library of Medicine)
abciximab (UNII: X85G7936GV) (abciximab - UNII:X85G7936GV)
Eli Lilly and Company
abciximab
abciximab 2 mg in 1 mL
PRESCRIPTION DRUG
Biologic Licensing Application
REOPRO- ABCIXIMAB INJECTION, SOLUTION ELI LILLY AND COMPANY ---------- REOPRO ABCIXIMAB FOR INTRAVENOUS ADMINISTRATION DESCRIPTION: Abciximab, ReoPro , is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation. Abciximab also binds to the vitronectin (α β ) receptor found on platelets and vessel wall endothelial and smooth muscle cells. The chimeric 7E3 antibody is produced by continuous perfusion in mammalian cell culture. The 47,615 dalton Fab fragment is purified from cell culture supernatant by a series of steps involving specific viral inactivation and removal procedures, digestion with papain and column chromatography. ReoPro is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 0.01 M sodium phosphate, 0.15 M sodium chloride and 0.001% polysorbate 80 in Water for Injection. No preservatives are added. CLINICAL PHARMACOLOGY: GENERAL- Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. The mechanism of action is thought to involve steric hindrance and/or conformational effects to block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. Abciximab binds with similar affinity to the vitronectin receptor, also known as the α β integrin. The vitronectin receptor mediates the procoagulant properties of platelets and the proliferative properties of vascular endothelial and smooth muscle cells. In _in vitro_ studies using a model cell line derived from mela 阅读完整的文件